ID

34540

Descrição

Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02468284

Link

https://clinicaltrials.gov/show/NCT02468284

Palavras-chave

  1. 19/01/2019 19/01/2019 -
  2. 22/05/2019 22/05/2019 -
Titular dos direitos

see on clinicaltrials.gov

Transferido a

19 de janeiro de 2019

DOI

Para um pedido faça login.

Licença

Creative Commons BY-NC 3.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Prostate Cancer NCT02468284

Eligibility Prostate Cancer NCT02468284

Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
has a histologically confirmed (gleason graded) adenocarcinoma of the prostate (all stages), for which endocrine therapy (except for neoadjuvant hormonal therapy) is indicated
Descrição

ID.1

Tipo de dados

boolean

has a prostate-specific antigen (psa) level ≥2.0 ng/ml at screening
Descrição

ID.2

Tipo de dados

boolean

has a screening serum testosterone level >150 ng/dl
Descrição

ID.3

Tipo de dados

boolean

has an eastern cooperative oncology group (ecog) score of ≤2
Descrição

ID.4

Tipo de dados

boolean

Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
has had previous or is currently under hormonal management of prostate cancer. however, hormonal therapy for a maximum duration of 6 months is accepted. this treatment should have been terminated at least 6 months prior to the screening visit
Descrição

ID.5

Tipo de dados

boolean

is currently treated with a 5-alpha reductase inhibitor
Descrição

ID.6

Tipo de dados

boolean

is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy
Descrição

ID.7

Tipo de dados

boolean

is in need of neoadjuvant hormonal therapy
Descrição

ID.8

Tipo de dados

boolean

has a history of bilateral orchiectomy, adrenalectomy, or hypophysectomy
Descrição

ID.9

Tipo de dados

boolean

Similar models

Eligibility Prostate Cancer NCT02468284

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
has a histologically confirmed (gleason graded) adenocarcinoma of the prostate (all stages), for which endocrine therapy (except for neoadjuvant hormonal therapy) is indicated
boolean
ID.2
Item
has a prostate-specific antigen (psa) level ≥2.0 ng/ml at screening
boolean
ID.3
Item
has a screening serum testosterone level >150 ng/dl
boolean
ID.4
Item
has an eastern cooperative oncology group (ecog) score of ≤2
boolean
Item Group
C0680251 (UMLS CUI)
ID.5
Item
has had previous or is currently under hormonal management of prostate cancer. however, hormonal therapy for a maximum duration of 6 months is accepted. this treatment should have been terminated at least 6 months prior to the screening visit
boolean
ID.6
Item
is currently treated with a 5-alpha reductase inhibitor
boolean
ID.7
Item
is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy
boolean
ID.8
Item
is in need of neoadjuvant hormonal therapy
boolean
ID.9
Item
has a history of bilateral orchiectomy, adrenalectomy, or hypophysectomy
boolean

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial